|
CORRESPONDENCE |
|
| Year : 2009 | Volume
: 54
| Issue : 2 | Page : 193-195 |
|
| ARNDT gottron scleromyxedema: Successful response to treatment with steroid minipulse and methotrexate |
|
|
Vandana Mehta, C Balachandran, Raghavendra Rao
Department of Skin and STD, Kasturba Hospital, Manipal - 576 104, Karnataka, India
| Date of Web Publication | 3-Jul-2009 |
Correspondence Address:
Vandana Mehta
Department of Skin and STD, Kasturba Hospital, Manipal - 576 104, Karnataka
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0019-5154.53183
|
|
How to cite this article:
Mehta V, Balachandran C, Rao R. ARNDT gottron scleromyxedema: Successful response to treatment with steroid minipulse and methotrexate. Indian J Dermatol 2009;54:193-5 |
How to cite this URL:
Mehta V, Balachandran C, Rao R. ARNDT gottron scleromyxedema: Successful response to treatment with steroid minipulse and methotrexate. Indian J Dermatol [serial online] 2009 [cited 2023 Nov 30];54:193-5. Available from: https://www.e-ijd.org/text.asp?2009/54/2/193/53183 |
Sir,
Scleromyxedema is a rare disorder of unknown cause, with fewer than 150 reported cases in literature. It usually affects middle-aged adults of 30-50 years and is clinically characterized by a widespread symmetric eruption of 2-3 mm firm, waxy, dome-shaped papules, commonly over the hands, forearms, head and neck region, upper trunk, and thighs. The characteristic is the arrangement of papules in a striking linear array with the surrounding skin being sclerodermoid. [1] We report a case of scleromyxedema who considerably improved with a trial of steroid oral minipulse and methotrexate.
A 43-year-old male farmer presented with a skin colored eruption on his body of 6 months duration. Initially, the lesions began as grouped skin-colored papules on his hands associated with mild pruritus and subsequently spread to the face, neck, shoulders, upper extremities, and the abdomen. There was no history of any systemic symptoms and his past medical and family history was noncontributory. On examination, facial and ear lobe infiltration was noted with prominent forehead creases. The skin of the forehead, neck, upper trunk, and arms was bound down and exhibited numerous 1-2 mm grouped skin colored papules [Figure 1] and [Figure 2]. Our patient was thoroughly investigated and results of his complete blood cell count, urinalysis, liver and renal parameters, thyroid profile, ECG, chest X-ray, ultrasound abdomen, and sugars were normal. ELISA for HIV was negative. Immunoglobulin profile showed elevated serum IgG 1797 (mg/dl) (normal 1200-1480 mg/dl), whereas IgA, IgM were normal. Biopsy features from the papule on the forearm showed features that are characteristic of scleromyxedema with special stains demonstrating mucin in the dermis.
In the literature, the terms lichen myxedematosus(LM), papular mucinosis, and scleromyxedema have often been used indiscriminately as synonyms, but most reported cases of LM without indication of the subtype appear infact to be cases of scleromyxedema. Actually, LM includes three distinct clinicopathologic subsets: a0 generalized papular and sclerodermoid form called as scleromyxedema with systemic even lethal manifestations, a localized papular form that does not run a disabling course and an atypical or intermediate form (not meeting the criteria for either scleromyxedema or the localised papular forms). [2] Patients of scleromyxedema may have a number of extracutaneous manifestations pertaining to the cardiovascular, pulmonary, gastrointestinal, rheumatologic, and central nervous systems. A paraproteinemia typically an IgGλ is observed in more than 80% patients. Microscopically, scleromyxedema is characterized by a triad of a diffuse deposit of mucin in the upper and mid reticular dermis, an increase in collagen deposition, and a marked proliferation of irregular arranged fibroblasts. The exact pathophysiologic mechanism that triggers excess mucin production by fibroblasts in scleromyxedema is unclear. Although this can be attributed to paraproteins according to previous studies, all patients of papular mucinosis do not have an identifiable paraprotein, which suggest the role of other cytokines as proliferative signals. [3]
The treatment of scleromyxedema remains a therapeutic challenge to the treating physician and despite anecdotal reports of success with various agents, no satisfactory treatments are currently available. [4]
Our patient was diagnosed as scleromyxedema clinically on the basis of a generalized papular and sclerodermoid eruption and histologically by the presence of mucin deposition fibrosis and fibroblast proliferation with a normal thyroid function. Extensive screening did not reveal any internal malignancy and although our patient had increased gamma globulin levels, we could not investigate this further due to financial constraints to support our diagnosis further. He was commenced on minipulse therapy with oral betamethasone six tablets to be taken twice weekly with weekly methotrexate 10 mgs. After 3 months of regular treatment, patient reported 75% reduction in the cutaneous induration. There were no other systemic complaints. Patient is currently on regular treatment and is doing well.
 References | |  |
| 1. | Heymann WR. Scleromyxedema. J Am Acad Dermatol 2007;57:890-1.  [PUBMED] [FULLTEXT] |
| 2. | Rongioletti F. Lichen myxedematosus (papular mucinosis): New concepts and perspectives for an old disease. Semin Cutan Med Surg 2006; 25: 100-3) [PUBMED] [FULLTEXT] |
| 3. | Cokonis Georgakis CD, Falasca G, Georgakis A, Heymann WR. Scleromyxedema. Clin Dermatol 2006;24:493-7. [PUBMED] [FULLTEXT] |
| 4. | Desai AD, James WD. Lichen myxedematosus. In: Lebwohl MG, Heymann WR, Berth - Jones J, Coulson IC, editors. Treatment of skin disease: c0 omprehensive therapeutic strategies. 2 nd ed. London (UK): Elsevier; 2006. p. 343-4. |
[Figure 1], [Figure 2] |
|
| This article has been cited by | | 1 |
Combination intravenous immunoglobulin, oral prednisone, and methotrexate for managing scleromyxedema: case report and literature discussion |
|
| Gaia Fasano, Giancarlo Valenti, Domenico D'Amico, Mario Valenti | | Dermatology Reports. 2023; | | [Pubmed] | [DOI] | | | 2 |
Early onset of scleromyxedema
Arndt-Gottron
associated with a monoclonal gammapathy: Successful treatment with intravenous immunoglobulins
|
|
| Asma Kefi, Fatima Jaziri, Khaoula Ben Abdelghani, Sami Turki | | Clinical Case Reports. 2022; 10(8) | | [Pubmed] | [DOI] | | | 3 |
Eponyms in dermatology linked to Gottron |
|
| Shreya K, Pooja Gupta, Dinesh P Asati, Priyanka Verma | | Indian Journal of Dermatology, Venereology and Leprology. 2022; 0: 1 | | [Pubmed] | [DOI] | | | 4 |
Monoclonal gammopathies of clinical significance (MGCS): In pursuit of optimal treatment |
|
| Artem Oganesyan, Andrew Gregory, Florent Malard, Nerses Ghahramanyan, Mohamad Mohty, Dickran Kazandjian, Arsène Mekinian, Yervand Hakobyan | | Frontiers in Immunology. 2022; 13 | | [Pubmed] | [DOI] | | | 5 |
Characterization of circulating myeloma tumor cells by next generation flowcytometry in scleromyxedema patient: a case report |
|
| Ruba Y. Taha, Saba Hasan, Firyal Ibrahim, Yannick Chantran, Hesham El Sabah, Siveen Sivaraman, Issam Al Bozom, Ahmad Al Sabbagh, Laurent Garderet, Halima El Omri | | Medicine. 2020; 99(27): e20726 | | [Pubmed] | [DOI] | | | 6 |
Treatment of scleromyxedema with lenalidomide, bortezomib and dexamethasone: A case report and review of the literature |
|
| Hninyee Win, Krisstina Gowin | | Clinical Case Reports. 2020; 8(12): 3042 | | [Pubmed] | [DOI] | | | 7 |
Pharmacotherapy of scleromyxedema |
|
| Elisa Cinotti,Franco Rongioletti | | Expert Opinion on Orphan Drugs. 2013; 1(10): 781 | | [Pubmed] | [DOI] | |
|
|
|
|
|
|
|
|
|
|
|
| Article Access Statistics | | | Viewed | 4818 | | | Printed | 146 | | | Emailed | 1 | | | PDF Downloaded | 122 | | | Comments | [Add] | | | Cited by others | 7 | | |
|
|
